Scientific Publications Search Search Author Impact Factor Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Beule, Dieter Dr. (4) Blankenstein, Thomas Prof. Dr. (2) Cakmak-Görür, Nese Dr. (1) Dörr, Jan Rafael (1) Haas, Simon Dr. rer. nat. (4) Holz, Maximilian (1) Höpken, Uta Elisabeth PD Dr. (1) Horne, Arik (1) Janz, Martin Dr. (5) Kempa, Stefan Dr. (1) Mathas, Stephan Dr. (4) Mertins, Philipp Dr. (3) Na, Il-Kang Dr. (3) Özerdem, Ceren (1) Pezzutto, Antonio Prof. Dr. (9) Popp, Oliver Dr. (2) Rhein, Simone Dr. (2) Sapozhnikova, Valeriia (1) Schmitt, Clemens Prof. Dr. (2) Solé Boldo, Llorenc Dr. rer. nat. (1) Strzelecka, Paulina Maria (1) Walther, Wolfgang Prof. Dr. (2) Willimsky, Gerald Dr. (2) Yousefian, Schayan (2) Ziehm, Matthias Dr. (1) 2013 (2) 2014 (2) 2015 (2) 2016 (1) 2019 (1) 2020 (11) 2021 (18) 2022 (19) 2023 (19) 2024 (18) AG Müller/Dechend (ECRC) (4) Anchored Signalling (1) Biobank (7) Bioinformatics and Omics Data Science (23) Bioinformatics of RNA Structure and Transcriptome Regulation (1) Biology of Malignant Lymphomas (10) Cancer Genetics and Cellular Stress Responses (2) Cardiac MRI (278) Cellular Neurosciences (3) Clinical Research Unit (1) Computational Regulatory Genomics (1) Developmental Biology / Signal Transduction (4) Epigenetic Regulation and Chromatin Architecture (2) Experimental Ultrahigh-Field MR (34) From Cell States to Function (1) Genetics and Genomics of Cardiovascular Diseases (5) Genetics of Congenital Heart Disease (1) Genomics (2) Hypertension-caused End-Organ Damage (4) Hypertension-Mediated End-Organ Damage (4) Immune Regulation and Cancer (1) Integrative Vascular Biology (6) Magnetic Resonance (34) (-) Mechanism-based Cancer Therapies (93) Microenvironmental Regulation in Autoimmunity and Cancer (2) Molecular Epidemiology (7) Molecular Immunology and Gene Therapy (2) Myology (7) Nephrology and Inflammatory Vascular Diseases (1) Neuroimmunology Laboratory (1) Non-coding RNAs and Mechanisms of Cytoplasmic Gene Regulation (4) Proteome Dynamics (4) Proteomics (3) Proteomics and Metabolomics (1) Psychoneuroimmunology (2) RNA Biology and Posttranscriptional Regulation (5) Structural Biology of Membrane-Associated Processes (3) Systems Biology Imaging (2) Systems Biology of Gene Regulatory Elements (7) Systems Hematology, Stem Cells & Precision Medicine (4) Translational Bioinformatics (6) Translational Oncology of Solid Tumors (2) Translational Tumorimmunology (1) Tumor heterogeneity and treatment resistance in pediatric cancer (1) 93 Results: Active Filter: Mechanism-based Cancer Therapies Sort: Result score Newest to oldest Oldest to newest February 20, 2024 / Sci Signal Activation of gp130 signaling in T cells drives T(H)17-mediated multi-organ autoimmunity F. Baumgartner S.A. Bamopoulos L. Faletti H.J. Hsiao M. Holz I. Gonzalez-Menendez L. Solé-Boldo A. Horne S. Gosavi C. Özerdem N. Singh S. Liebig S. Ramamoorthy M. Lehmann U. Demel A.A. Kühl T. Wartewig J. Ruland F.T. Wunderlich M. Schick W. Walther S. Rose-John S. Haas L. Quintanilla-Martinez S. Feske S. Ehl R. Glauben U. Keller April 08, 2024 / Clin Res Cardiol Association of an impaired GH‑IGF‑I axis with cardiac wasting in patients with advanced cancer A.K. Fröhlich J. Porthun K.M. Talha A. Lena S. Hadzibegovic U. Wilkenshoff F. Sonntag A. Nikolski L.V. Ramer T. Zeller U. Keller L. Bullinger S.D. Anker W. Haverkamp S. von Haehling W. Doehner U. Rauch C. Skurk J.G.F. Cleland J. Butler A.J.S. Coats U. Landmesser M. Karakas M.S. Anker August, 2024 / Ann Hematol Plasmapheresis effectively abrogates severe liver toxicity of pegaspargase in a patient with acute lymphoblastic leukemia M. Tölle N. Gökbuget S. Habringer U. Keller S. Schwartz February, 2024 / Oral Oncol Molecular subtyping of head and neck cancer - Clinical applicability and correlations with morphological characteristics F. Stögbauer R. Otto K. Jöhrens I. Tinhofer U. Keilholz C. Poremba U. Keller U. Leser W. Weichert M. Boxberg K. Klinghammer January 03, 2024 / Case Rep Hematol Renal extramedullary hematopoiesis in mast cell leukemia with bone marrow fibrosis D.T. Rieke L.K. Schmalbrock J. Ihlow K. Kleo A.C. von Brünneck F. Nolte U. Keller S. Ochsenreither April, 2024 / Nuklearmedizin CXCR4-gerichtete Theranostics in der Hämato-Onkologie: Möglichkeiten und Herausforderungen [CXCR4-targeted theranostics in hematooncology: opportunities and challenges] R. Werner A. Haug C. Buske S. Heidegger A.L. Illert F. Bassermann P. Herhaus A. Buck J. Duell M.S. Topp S. Kraus H. Einsele C. Lapa M. Raderer G. Lenz S. Habringer B. von Tresckow U. Keller September 05, 2024 / N Engl J Med Teclistamab-induced remission in refractory systemic lupus erythematosus T. Alexander J. Krönke Q. Cheng U. Keller G. Krönke July 15, 2024 / Clin Chem Lab Med Simplified preanalytical laboratory procedures for therapeutic drug monitoring (TDM) in patients treated with high-dose methotrexate (HD-MTX) and glucarpidase F.L. Knörnschild S. Liebig P. Kießling M. Prpic T. Kim U. Keller K. Kappert S. Schwartz A. Jahic July 31, 2024 Abklärung und OP-Indikationen bei malignen Lymphknoten des unteren GI-Traktes U. Keller I. Merz September 16, 2024 / Blood Cancer J Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy S. Gross J. Ihlow L. Busack K. Adamiak J. Schrezenmeier J. Jesse M. Schwarz A. Flörcken L.G. Vuong K. Rieger J. Krönke P. le Coutre V. Boldt A.C. von Brünneck D. Horst T. Burmeister I.W. Blau U. Keller L. Bullinger J. Westermann Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next › Last page Last »
February 20, 2024 / Sci Signal Activation of gp130 signaling in T cells drives T(H)17-mediated multi-organ autoimmunity F. Baumgartner S.A. Bamopoulos L. Faletti H.J. Hsiao M. Holz I. Gonzalez-Menendez L. Solé-Boldo A. Horne S. Gosavi C. Özerdem N. Singh S. Liebig S. Ramamoorthy M. Lehmann U. Demel A.A. Kühl T. Wartewig J. Ruland F.T. Wunderlich M. Schick W. Walther S. Rose-John S. Haas L. Quintanilla-Martinez S. Feske S. Ehl R. Glauben U. Keller
April 08, 2024 / Clin Res Cardiol Association of an impaired GH‑IGF‑I axis with cardiac wasting in patients with advanced cancer A.K. Fröhlich J. Porthun K.M. Talha A. Lena S. Hadzibegovic U. Wilkenshoff F. Sonntag A. Nikolski L.V. Ramer T. Zeller U. Keller L. Bullinger S.D. Anker W. Haverkamp S. von Haehling W. Doehner U. Rauch C. Skurk J.G.F. Cleland J. Butler A.J.S. Coats U. Landmesser M. Karakas M.S. Anker
August, 2024 / Ann Hematol Plasmapheresis effectively abrogates severe liver toxicity of pegaspargase in a patient with acute lymphoblastic leukemia M. Tölle N. Gökbuget S. Habringer U. Keller S. Schwartz
February, 2024 / Oral Oncol Molecular subtyping of head and neck cancer - Clinical applicability and correlations with morphological characteristics F. Stögbauer R. Otto K. Jöhrens I. Tinhofer U. Keilholz C. Poremba U. Keller U. Leser W. Weichert M. Boxberg K. Klinghammer
January 03, 2024 / Case Rep Hematol Renal extramedullary hematopoiesis in mast cell leukemia with bone marrow fibrosis D.T. Rieke L.K. Schmalbrock J. Ihlow K. Kleo A.C. von Brünneck F. Nolte U. Keller S. Ochsenreither
April, 2024 / Nuklearmedizin CXCR4-gerichtete Theranostics in der Hämato-Onkologie: Möglichkeiten und Herausforderungen [CXCR4-targeted theranostics in hematooncology: opportunities and challenges] R. Werner A. Haug C. Buske S. Heidegger A.L. Illert F. Bassermann P. Herhaus A. Buck J. Duell M.S. Topp S. Kraus H. Einsele C. Lapa M. Raderer G. Lenz S. Habringer B. von Tresckow U. Keller
September 05, 2024 / N Engl J Med Teclistamab-induced remission in refractory systemic lupus erythematosus T. Alexander J. Krönke Q. Cheng U. Keller G. Krönke
July 15, 2024 / Clin Chem Lab Med Simplified preanalytical laboratory procedures for therapeutic drug monitoring (TDM) in patients treated with high-dose methotrexate (HD-MTX) and glucarpidase F.L. Knörnschild S. Liebig P. Kießling M. Prpic T. Kim U. Keller K. Kappert S. Schwartz A. Jahic
July 31, 2024 Abklärung und OP-Indikationen bei malignen Lymphknoten des unteren GI-Traktes U. Keller I. Merz
September 16, 2024 / Blood Cancer J Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy S. Gross J. Ihlow L. Busack K. Adamiak J. Schrezenmeier J. Jesse M. Schwarz A. Flörcken L.G. Vuong K. Rieger J. Krönke P. le Coutre V. Boldt A.C. von Brünneck D. Horst T. Burmeister I.W. Blau U. Keller L. Bullinger J. Westermann